C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review.
AffiliationOur Lady's Hospice & Care Services; The Cleveland Clinic Taussig Cancer Institute
MetadataShow full item record
CitationC-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. 2015, 10 (12):e0143080 PLoS ONE
AbstractA systematic literature review was done to determine the relationship between elevated CRP and prognosis in people with solid tumors. C-reactive protein (CRP) is a serum acute phase reactant and a well-established inflammatory marker. We also examined the role of CRP to predict treatment response and tumor recurrence.
MeSH (Medical Subject Heading) terms were used to search multiple electronic databases (PubMed, EMBASE, Web of Science, SCOPUS, EBM-Cochrane). Two independent reviewers selected research papers. We also included a quality Assessment (QA) score. Reports with QA scores <50% were excluded. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) methodology was utilized for this review (S1 PRISMA Checklist).
271 articles were identified for final review. There were 45% prospective studies and 52% retrospective. 264 had intermediate QA score (≥50% but <80%); Seven were adequate (80% -100%); A high CRP was predictive of prognosis in 90% (245/271) of studies-80% of the 245 studies by multivariate analysis, 20% by univariate analysis. Many (52%) of the articles were about gastrointestinal malignancies (GI) or kidney malignancies. A high CRP was prognostic in 90% (127 of 141) of the reports in those groups of tumors. CRP was also prognostic in most reports in other solid tumors primary sites.
A high CRP was associated with higher mortality in 90% of reports in people with solid tumors primary sites. This was particularly notable in GI malignancies and kidney malignancies. In other solid tumors (lung, pancreas, hepatocellular cancer, and bladder) an elevated CRP also predicted prognosis. In addition there is also evidence to support the use of CRP to help decide treatment response and identify tumor recurrence. Better designed large scale studies should be conducted to examine these issues more comprehensively.
The following license files are associated with this item:
- Creative Commons
- Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis.
- Authors: Dai J, Tang K, Xiao W, Yu G, Zeng J, Li W, Zhang YQ, Xu H, Chen ZQ, Ye ZQ
- Issue date: 2014
- Exosomal microRNAs as potential circulating biomarkers in gastrointestinal tract cancers: a systematic review protocol.
- Authors: Gheytanchi E, Madjd Z, Janani L, Rasti A, Ghods R, Atyabi F, Asadi-Lari MH, Babashah S
- Issue date: 2017 Nov 17
- C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
- Authors: Obata J, Kikuchi E, Tanaka N, Matsumoto K, Hayakawa N, Ide H, Miyajima A, Nakagawa K, Oya M
- Issue date: 2013 Nov
- [Prognostic importance of plasma C-reactive protein (CRP) in oncology].
- Authors: Deme D, Telekes A
- Issue date: 2017 Feb
- Elevated CRP levels predict poor outcome and tumor recurrence in patients with thymic epithelial tumors: A pro- and retrospective analysis.
- Authors: Janik S, Bekos C, Hacker P, Raunegger T, Ghanim B, Einwallner E, Beer L, Klepetko W, Müllauer L, Ankersmit HJ, Moser B
- Issue date: 2017 Jul 18